Markets:

Overview

News

Currencies

International

Treasuries

EyePoint, Inc. - Common Stock (NQ:EYPT)

4.870 -9.880 (-66.98%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about EyePoint, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Let's take a look at the stocks that are in motion in today's session. ↗

Today 15:00 EDT

Via Chartmill

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

Today 12:30 EDT

Via Chartmill

EyePoint’s DURAVYU Misses Primary Endpoint in Phase III Wet AMD Trial ↗

Today 12:02 EDT

Eyepoint Pharmaceuticals (NASDAQ:EYPT) reported topline results from LUGANO, the first of two Phase III trials evaluating DURAVYU, a vorolanib intravitreal insert, in patients with wet age-related...

Via MarketBeat

There are notable gap-ups and gap-downs in today's session. ↗

Today 10:30 EDT

Via Chartmill

EyePoint (NASDAQ:EYPT) Rallies Despite Wider Q2 Loss as Phase 3 Data Nears ↗

August 05, 2026

Via Chartmill

EyePoint Inc. (NASDAQ:EYPT) Revenue Beats Estimates, Earnings Miss in Q1 2026 Report ↗

May 06, 2026

Via Chartmill

Topics Earnings

EyePoint Inc (NASDAQ:EYPT) Stock Falls on Q4 Earnings and Revenue Miss ↗

March 04, 2026

Via Chartmill

These stocks are moving in today's pre-market session ↗

Today 8:30 EDT

Via Chartmill

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗

June 29, 2026

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Via The Motley Fool

EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears ↗

May 26, 2026

Eyepoint Pharmaceuticals (NASDAQ:EYPT) executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as...

Via MarketBeat

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗

May 17, 2026

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗

May 17, 2026

This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.

Via The Motley Fool

Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗

May 17, 2026

This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.

Via The Motley Fool

Topics Regulatory Compliance

EyePoint (EYPT) Q1 2026 Earnings Transcript ↗

May 07, 2026

EyePoint (EYPT) Q1 2026 Earnings Transcript

Via The Motley Fool

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.

Via The Motley Fool

Topics Regulatory Compliance

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗

March 16, 2026

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗

March 16, 2026

Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment ↗

March 15, 2026

EyePoint develops sustained-release treatments for retinal diseases, leveraging proprietary technology and strategic industry partnerships.

Via The Motley Fool

EyePoint (EYPT) Q4 2025 Earnings Call Transcript ↗

March 04, 2026

EyePoint (EYPT) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data

February 16, 2026

The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in...

Via MarketMinute

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...

Via MarketMinute

Topics Artificial Intelligence ETFs Initial Public Offering

Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles

January 08, 2026

In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index (RUT) surged to a new record high on January 8, 2026, signaling a definitive breakout for small-cap stocks. As...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens

January 02, 2026

As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

The Small-Cap Renaissance: Why 2026 is the Year of the Russell 2000 and XSU

January 01, 2026

As the sun rises on January 1, 2026, the financial landscape is witnessing a profound shift that many analysts have anticipated for years: the definitive return of the U.S. small-cap sector. After a...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy

December 31, 2025

As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗

December 22, 2025

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Via The Motley Fool

Topics Regulatory Compliance

EyePoint (EYPT) Q3 2025 Earnings Call Transcript ↗

November 05, 2025

EyePoint (EYPT) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Shares Drop on Q3 Earnings and Revenue Miss ↗

November 05, 2025

EyePoint Pharmaceuticals stock falls after Q3 2025 earnings miss estimates. Despite the financial setback, its key DURAVYU trials for wet AMD are fully enrolled and on track for 2026 data.

Via Chartmill

Topics Earnings

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.